Review



recombinant galectin‐3 (r‐gal3  (PeproTech)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    PeproTech recombinant galectin‐3 (r‐gal3
    Galectin‐3 promoted cancer malignancy of HER2‐positive breast cancer cells. Western blot analysis of galectin‐3, HER2, and β‐actin in (a) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL <t>r‐Gal3</t> for 3 days; (b) JIMT1 cells transfected with siRNA‐NC, siRNA‐533, or siRNA‐571; and (c) JIMT1 cells treated with 0, 10, or 20 μg/mL GB1107 for 3 days. Cell viability curves for (d) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; and (e) siRNA‐NC, siRNA‐533, siRNA‐571, and JIMT1 cells treated with 10 μg/mL GB1107 for 3 days. (f) Healing assays; (g) colony formation assays; and (h) transwell assays in pcDNA‐NC, pcDNA‐ LGALS3 , siRNA‐NC, and siRNA‐533 cells. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)
    Recombinant Galectin‐3 (R‐Gal3, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant galectin‐3 (r‐gal3/product/PeproTech
    Average 90 stars, based on 1 article reviews
    recombinant galectin‐3 (r‐gal3 - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "Galectin‐3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2 ‐positive breast cancer cells"

    Article Title: Galectin‐3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2 ‐positive breast cancer cells

    Journal: Thoracic Cancer

    doi: 10.1111/1759-7714.14474

    Galectin‐3 promoted cancer malignancy of HER2‐positive breast cancer cells. Western blot analysis of galectin‐3, HER2, and β‐actin in (a) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; (b) JIMT1 cells transfected with siRNA‐NC, siRNA‐533, or siRNA‐571; and (c) JIMT1 cells treated with 0, 10, or 20 μg/mL GB1107 for 3 days. Cell viability curves for (d) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; and (e) siRNA‐NC, siRNA‐533, siRNA‐571, and JIMT1 cells treated with 10 μg/mL GB1107 for 3 days. (f) Healing assays; (g) colony formation assays; and (h) transwell assays in pcDNA‐NC, pcDNA‐ LGALS3 , siRNA‐NC, and siRNA‐533 cells. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)
    Figure Legend Snippet: Galectin‐3 promoted cancer malignancy of HER2‐positive breast cancer cells. Western blot analysis of galectin‐3, HER2, and β‐actin in (a) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; (b) JIMT1 cells transfected with siRNA‐NC, siRNA‐533, or siRNA‐571; and (c) JIMT1 cells treated with 0, 10, or 20 μg/mL GB1107 for 3 days. Cell viability curves for (d) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; and (e) siRNA‐NC, siRNA‐533, siRNA‐571, and JIMT1 cells treated with 10 μg/mL GB1107 for 3 days. (f) Healing assays; (g) colony formation assays; and (h) transwell assays in pcDNA‐NC, pcDNA‐ LGALS3 , siRNA‐NC, and siRNA‐533 cells. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)

    Techniques Used: Western Blot, Transfection



    Similar Products

    recombinant galectin‐3 (r‐gal3  (PeproTech)
    90
    PeproTech recombinant galectin‐3 (r‐gal3
    Galectin‐3 promoted cancer malignancy of HER2‐positive breast cancer cells. Western blot analysis of galectin‐3, HER2, and β‐actin in (a) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL <t>r‐Gal3</t> for 3 days; (b) JIMT1 cells transfected with siRNA‐NC, siRNA‐533, or siRNA‐571; and (c) JIMT1 cells treated with 0, 10, or 20 μg/mL GB1107 for 3 days. Cell viability curves for (d) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; and (e) siRNA‐NC, siRNA‐533, siRNA‐571, and JIMT1 cells treated with 10 μg/mL GB1107 for 3 days. (f) Healing assays; (g) colony formation assays; and (h) transwell assays in pcDNA‐NC, pcDNA‐ LGALS3 , siRNA‐NC, and siRNA‐533 cells. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)
    Recombinant Galectin‐3 (R‐Gal3, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant galectin‐3 (r‐gal3/product/PeproTech
    Average 90 stars, based on 1 article reviews
    recombinant galectin‐3 (r‐gal3 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    recombinant galectin-3 (r-gal3)  (Galectin Therapeutics)
    90
    Galectin Therapeutics recombinant galectin-3 (r-gal3)
    Galectin‐3 promoted cancer malignancy of HER2‐positive breast cancer cells. Western blot analysis of galectin‐3, HER2, and β‐actin in (a) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL <t>r‐Gal3</t> for 3 days; (b) JIMT1 cells transfected with siRNA‐NC, siRNA‐533, or siRNA‐571; and (c) JIMT1 cells treated with 0, 10, or 20 μg/mL GB1107 for 3 days. Cell viability curves for (d) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; and (e) siRNA‐NC, siRNA‐533, siRNA‐571, and JIMT1 cells treated with 10 μg/mL GB1107 for 3 days. (f) Healing assays; (g) colony formation assays; and (h) transwell assays in pcDNA‐NC, pcDNA‐ LGALS3 , siRNA‐NC, and siRNA‐533 cells. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)
    Recombinant Galectin 3 (R Gal3), supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant galectin-3 (r-gal3)/product/Galectin Therapeutics
    Average 90 stars, based on 1 article reviews
    recombinant galectin-3 (r-gal3) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Galectin‐3 promoted cancer malignancy of HER2‐positive breast cancer cells. Western blot analysis of galectin‐3, HER2, and β‐actin in (a) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; (b) JIMT1 cells transfected with siRNA‐NC, siRNA‐533, or siRNA‐571; and (c) JIMT1 cells treated with 0, 10, or 20 μg/mL GB1107 for 3 days. Cell viability curves for (d) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; and (e) siRNA‐NC, siRNA‐533, siRNA‐571, and JIMT1 cells treated with 10 μg/mL GB1107 for 3 days. (f) Healing assays; (g) colony formation assays; and (h) transwell assays in pcDNA‐NC, pcDNA‐ LGALS3 , siRNA‐NC, and siRNA‐533 cells. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)

    Journal: Thoracic Cancer

    Article Title: Galectin‐3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2 ‐positive breast cancer cells

    doi: 10.1111/1759-7714.14474

    Figure Lengend Snippet: Galectin‐3 promoted cancer malignancy of HER2‐positive breast cancer cells. Western blot analysis of galectin‐3, HER2, and β‐actin in (a) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; (b) JIMT1 cells transfected with siRNA‐NC, siRNA‐533, or siRNA‐571; and (c) JIMT1 cells treated with 0, 10, or 20 μg/mL GB1107 for 3 days. Cell viability curves for (d) pcDNA‐NC, pcDNA‐ LGALS3 , SKBR3, and SKBR3 cells treated with 100 ng/mL r‐Gal3 for 3 days; and (e) siRNA‐NC, siRNA‐533, siRNA‐571, and JIMT1 cells treated with 10 μg/mL GB1107 for 3 days. (f) Healing assays; (g) colony formation assays; and (h) transwell assays in pcDNA‐NC, pcDNA‐ LGALS3 , siRNA‐NC, and siRNA‐533 cells. The significant differences are indicated by asterisk (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001)

    Article Snippet: Recombinant galectin‐3 (r‐Gal3) was obtained from PeproTech.

    Techniques: Western Blot, Transfection